Current eye research · 2025
Effect of Meibomian Gland Expression on Optical Quality in Patients with Meibomian Gland Dysfunction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Hongzhe, Tong Wentao, Hu Man, Meng Ziqi, Chang Pingjun, Zhao Yune
Аннотация
PURPOSE: To evaluate the changes in meibomian gland function, ocular surface parameters, and optical quality before and after meibomian gland expression in patients with meibomian gland dysfunction (MGD).
METHODS: Patients with MGD underwent meibomian gland expression once weekly for 4 consecutive weeks. Comprehensive assessments, including the Ocular Surface Disease Index questionnaire, tear break-up time, corneal fluorescein staining, lid margin abnormality grading, meibum expressibility and quality evaluations, Schirmer I test (SIT), as well as optical quality examinations using the Pentacam and Optical Quality Analysis System II, were conducted before and after the treatment.
RESULTS: 124 eyes of 62 patients were included in the study. Most meibomian gland function and ocular surface parameters showed significant improvement after treatment. Except for and coma (p = .029), no other significant changes in optical quality were observed. Changes in SIT were significantly correlated with changes in total corneal high-order aberrations (tHOA-4mm) (r = -.224, p = .019). Changes in objective scattering index were significantly associated with changes in spherical aberration (r = .219, p = .022), trefoil (r = .797, p < .001), total high-order aberrations (r = .408, p < .001) and total corneal spherical aberration (r = .590, p < .001).
CONCLUSION: Meibomian gland expression effectively improves meibomian gland function and ocular surface parameters. However, it does not appear to significantly impact optical quality in patients with MGD.
METHODS: Patients with MGD underwent meibomian gland expression once weekly for 4 consecutive weeks. Comprehensive assessments, including the Ocular Surface Disease Index questionnaire, tear break-up time, corneal fluorescein staining, lid margin abnormality grading, meibum expressibility and quality evaluations, Schirmer I test (SIT), as well as optical quality examinations using the Pentacam and Optical Quality Analysis System II, were conducted before and after the treatment.
RESULTS: 124 eyes of 62 patients were included in the study. Most meibomian gland function and ocular surface parameters showed significant improvement after treatment. Except for and coma (p = .029), no other significant changes in optical quality were observed. Changes in SIT were significantly correlated with changes in total corneal high-order aberrations (tHOA-4mm) (r = -.224, p = .019). Changes in objective scattering index were significantly associated with changes in spherical aberration (r = .219, p = .022), trefoil (r = .797, p < .001), total high-order aberrations (r = .408, p < .001) and total corneal spherical aberration (r = .590, p < .001).
CONCLUSION: Meibomian gland expression effectively improves meibomian gland function and ocular surface parameters. However, it does not appear to significantly impact optical quality in patients with MGD.